Amycretin is Novo Nordisk's investigational unimolecular agonist - a single molecule that activates both the amylin and GLP-1 receptors. Novo is developing it in two formats: a once-daily oral tablet and a once-weekly subcutaneous injection.

How much weight loss did amycretin show?

In a Phase 2 trial in people with type-2 diabetes, once-weekly subcutaneous amycretin produced weight loss of up to about 14.5% versus 2.6% with placebo, and once-daily oral amycretin up to about 10.1% versus 2.5%. Earlier obesity Phase 1 data drew attention for the scale of reduction over a short dosing period.

Why does amycretin matter if CagriSema already combines amylin and GLP-1?

CagriSema combines two separate molecules. Amycretin folds both activities into one molecule, which simplifies formulation and, critically, makes an oral version feasible - something a two-peptide combination cannot easily achieve.

Can you buy amycretin as a research compound?

Amycretin is a proprietary Novo Nordisk molecule and is not catalogued by research-compound suppliers. New-U does not sell amycretin. The established amylin and GLP-1 research references - cagrilintide and semaglutide - are catalogued as lyophilised reference peptides, research use only, not for human consumption.

Shop by goal

Metabolic Signalling

GH-Axis Research

Muscle & IGF Research

Tissue and Cellular Models

Regenerative Research

Cellular Senescence Research

Cognitive Research

Multi-Compound Blends

Popular compounds

Research resources

Certificates of Analysis

Amycretin: A Research Guide to Novo Nordisk’s Unimolecular Amylin + GLP-1 Agonist

Q: Is amycretin approved?

No. As of mid-2026 amycretin has no marketing authorisation anywhere in the world. It has completed early-phase and Phase 2 trials, with Phase 3 planned. The FDA, MHRA and EMA have not approved it.

Short answer: amycretin is one molecule that does two jobs — a Novo Nordisk unimolecular agonist that activates both the amylin and GLP-1 receptors. Its headline feature is format: Novo is developing it as both a once-daily oral tablet and a once-weekly injection . A Phase 2 trial in type-2 diabetes reported up to ~14.5% weight loss (subcutaneous) and ~10.1% (oral) ; earlier obesity Phase 1 data drew attention for the scale of reduction over a short period. It has no marketing authorisation anywhere as of mid-2026, with Phase 3 planned. New-U does not sell amycretin. Part of our next obesity-research wave overview.

Plain-English summary. Amycretin is an unapproved, investigational Novo Nordisk molecule. The FDA, MHRA and EMA have not authorised it. This page is general information, not legal or medical advice; do not use unapproved compounds on people.

What amycretin actually is

Amycretin is a unimolecular agonist — a single engineered molecule that hits two receptors at once: the amylin receptor and the GLP-1 receptor . That is the same two-pathway idea behind CagriSema, but achieved inside one molecule rather than by combining two. The single-molecule approach is what makes an oral formulation realistic.

The oral-and-injectable story

Novo is developing amycretin in two formats, which is unusual and strategically deliberate:

Once-weekly subcutaneous — the high-efficacy injectable, competing head-to-head with the weekly incretins.

Once-daily oral — a tablet for patients who will not or cannot inject. Oral peptide delivery is hard (peptides are normally digested), so a peptide that survives oral dosing is a meaningful engineering result.

For the broader oral-vs-injectable question across the class, see our explainer on oral vs injectable GLP-1 research.

Why amylin + GLP-1 in one molecule

The two pathways are complementary, not redundant:

GLP-1 receptor — appetite suppression, slowed gastric emptying, glucose-dependent insulin secretion.

Amylin receptor — a distinct satiety signal that appears to restore leptin sensitivity, sharpening the “full” response.

Stacking them in a single molecule means one pharmacokinetic profile to manage instead of two, and one manufacturing stream — a simplification that matters at population scale.

The trial evidence

The subcutaneous Phase 1b/2a results were published in The Lancet (2025). The most concrete efficacy readout to date is the Phase 2 trial in type-2 diabetes (n=448, patients inadequately controlled on metformin with or without an SGLT2 inhibitor):

Formulation Weight loss vs placebo Population Once-weekly subcutaneous up to ~−14.5% (placebo ~−2.6%) Type-2 diabetes Phase 2 Once-daily oral up to ~−10.1% (placebo ~−2.5%) Type-2 diabetes Phase 2

Mean baseline weight in that trial was ~101.1 kg, and HbA1c fell significantly alongside weight. Adverse events were predominantly gastrointestinal and mostly mild-to-moderate, consistent with the incretin and amylin classes. Novo Nordisk has stated it plans to initiate Phase 3 trials across multiple indications.

A note on the numbers. Weight-loss percentages are not comparable across trials with different populations and durations. The diabetes population above typically loses less weight than an obesity-only cohort, so amycretin’s obesity-trial figures may read differently. Treat each number as belonging to its specific trial.

How amycretin compares

Compound Mechanism Format Status Amycretin Amylin + GLP-1 (one molecule) Oral & injectable Phase 3 planned CagriSema Amylin + GLP-1 (two molecules) Injectable NDA filed Petrelintide Amylin only Injectable Phase 3 planned Orforglipron GLP-1 (small molecule) Oral Submissions filed

Amycretin and research compounds

Amycretin is a proprietary Novo Nordisk molecule, not a catalogued reference peptide. New-U does not sell amycretin. The established, verifiable research references covering its two pathways are:

Cagrilintide — the amylin-analogue reference.

Semaglutide — the GLP-1 reference.

Each ships as a sealed, lyophilised reference peptide verified to >99% HPLC purity with a per-batch Certificate of Analysis — research use only, not for human consumption .

Frequently Asked Questions

What is amycretin? A Novo Nordisk unimolecular agonist of the amylin and GLP-1 receptors, in oral and injectable development.

Is amycretin approved? No. As of mid-2026 it has no marketing authorisation; Phase 3 is planned.

How much weight loss? Up to ~14.5% (SC) and ~10.1% (oral) in a Phase 2 diabetes trial; obesity-cohort figures differ.

Why not just use CagriSema? Amycretin packs both activities into one molecule, enabling an oral tablet — a two-peptide combination cannot easily do that.

Can I buy amycretin for research? No — it is proprietary. New-U catalogues the amylin and GLP-1 references (cagrilintide, semaglutide) instead. Research use only.

Primary sources & further reading

The Lancet — Amycretin, a unimolecular GLP-1 and amylin receptor agonist (subcutaneous): Phase 1b/2a (2025)

Novo Nordisk — Amycretin Phase 2 (type-2 diabetes) results

U.S. National Library of Medicine — PubMed: amycretin

ClinicalTrials.gov — amycretin trial registry

U.S. FDA — FDA (no amycretin approval as of publication)

External links are provided for research reference only; New-U is not affiliated with the cited organisations and links carry no endorsement either way.

From the Lab - Peptides on LinkedIn & Facebook

Lab-Verified Amylin & GLP-1 References

New-U Research Compounds catalogues cagrilintide and semaglutide — the amylin and GLP-1 research references — as sealed 10-vial packs of lyophilised reference peptide, independently verified by Janoshik and Freedom Diagnostics for >99% HPLC purity, with a per-batch Certificate of Analysis. Research use only — not for human consumption.

Research-grade · >99% HPLC purity · COA per lot

Buy research peptides from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research

Support

Ways to Pay

Shop by goal

Muscle & IGF Research

Tissue and Cellular Models

Regenerative Research

Cellular Senescence Research

Cognitive Research

Multi-Compound Blends

Shop by compound

CJC-1295 (without DAC)

Shop by region

Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.

Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.